WinstonWınston
Back
Viemed Healthcare logo

Viemed Healthcare

VMD
67
Medical - Care Facilities · Healthcare
Exchange
NASDAQ
Winston Score
67
Winston is curious
A decent business — some strong pillars, some weaker.
Data as of Aug 23, 2026 · filings through Jun 30, 2026
How the score breaks down
Quality
Good
Growth
Good
Cash Flow
Strong
Stability
Exceptional
Valuation
Good

Winston Score History

The full picture

Viemed Healthcare is a home medical equipment company that helps people with breathing problems live at home instead of in a hospital. Its main service is providing ventilators and respiratory therapy to patients with chronic lung diseases like COPD. The company works closely with doctors and hospitals to set up and manage these breathing devices in patients' homes across the United States and Canada.

Viemed makes money by renting medical equipment to patients and billing their insurance companies, including Medicare and Medicaid, on a recurring basis. This subscription-like billing model creates steady, predictable revenue, and the company's clinical respiratory therapists who visit patients at home give it an edge over simpler equipment suppliers. With a market cap around $400 million, Viemed is a small but focused player in home respiratory care. The key growth driver is the aging U.S. population and the ongoing shift toward treating chronic conditions at home, though heavy reliance on government reimbursement rates remains a significant risk if Medicare policies change.

Growth Profile

When traditional metrics don't capture the full picture, these are the signals growth stock investors use instead.

Revenue Growth

+23.9% YoY

YoY Growth Rate

Steady revenue growth

EPS Growth

-12.4% YoY

YoY Growth Rate

Earnings declining

Insider Activity

13.7%ownership

Declining

Insider ownership declining — could be dilution or selling

Cash Position

Cash flow positive

$14M cash & investments

Quarterly Free Cash Flow

↓ Burn rate worsening

Company generates more cash than it spends — no dilution risk from fundraising

Growth + cash flow

Viemed Healthcare is a rare growth stock that's already generating positive cash flow while growing at 24%. The Winston Score doesn't fully credit this transition from "burner" to "earner."

The Winston Score above measures business quality today. Growth stocks often score lower because they invest in the future rather than maximising current profits. These metrics show what matters most for evaluating that future.

Score breakdown

Every number that matters to educated investors.

Each metric is explained in plain language so you know exactly what you're looking at. Start your free trial now.

Quality

Profit per sale
Gross Margin
57.2%
Premium pricing power — 57.2% gross margin
Profit after running costs
Operating Margin
6.5%
Modest — 6.5% operating margin
Return on the money invested
ROCE
16.1%
Strong — 16.1% return on capital

ROIC between 15% and 25%. Every dollar invested in the business earns 15 to 25 cents back per year.

Full breakdown available with your free trial

See every metric, trend, and what it means for this stock.

Try free

Growth

Sales growth
Sales YoY
+25.2%
Fast-growing sales (+25.2% YoY)
Profit growth
EPS YoY
+4.9%
Modest earnings growth (+4.9% YoY)

Single-digit earnings growth — steady but not exciting.

How steady the profit is
EPS Consistency
5/8 quarters
Mixed — about half the quarters showed growth

Full breakdown available with your free trial

See every metric, trend, and what it means for this stock.

Try free

Cash Flow

Profit that turns into cash
Cash Conversion
419%
Turns 419% of profit into real cash
Spare cash per sale
FCF Margin
9.7%
Modest free cash flow (9.7%)

FCF margin between 0% and 10%. Some cash from sales, but not a lot.

Full breakdown available with your free trial

See every metric, trend, and what it means for this stock.

Try free

Stability

What it owes vs what it owns
Debt / Equity
0.06
Conservative — low debt load (0.06)
Covers its interest
Interest Cover
17.25x
Comfortably covers interest (17.2x)

Interest coverage above 8. Profits cover interest many times over.

Full breakdown available with your free trial

See every metric, trend, and what it means for this stock.

Try free

Valuation

Price vs profit
P/E Ratio (TTM)
23.5x
no trend
Growth-priced — P/E 23.5

P/E above the market average. People are paying up for expected growth.

Cheaper or dearer next year
P/E vs Forward
+2.1
GROWING
Earnings expected to grow — slightly cheaper on forward P/E

Full breakdown available with your free trial

See every metric, trend, and what it means for this stock.

Try free

Dividends

Not applicable for this business.
🔒 See full fundamentals and if they are improving or declining — click here for your free trial now.
Start free trial